FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer

被引:51
作者
Oku, S
Nakagawa, K
Momose, T
Kumakura, Y
Abe, A
Watanabe, T
Ohtomo, K
机构
[1] Univ Tokyo Hosp, Dept Radiol, Bunkyo Ku, Tokyo 1138655, Japan
[2] Univ Tokyo Hosp, Dept Surg Oncol, Bunkyo Ku, Tokyo 1138655, Japan
关键词
FDG-PET; Standardized Uptake Value; rectal cancer; prognostic indicator;
D O I
10.1007/BF02990079
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In the management of rectal cancer after the combined therapy of the radiation and surgical operation, the evaluation of the prognosis is important. Although fluoro-18-deoxyglucose positron emission tomography (FDG-PET) is considered as a useful tool for evaluation of therapeutic effect of this cancer as well as the other cancers, however, there are few articles that clearly describe the appropriate procedure of the FDG-PET in order to obtain the best prognostic value. The purpose of the present study is to compare several variations of a semi-quantification method, the Standardized Uptake Values (SUV) and to determine the most appropriate parameter for the prognostic prediction and to propose the quantitative guideline of the FDG-PET. Especially, the authors focused on the SUV after radiotherapy, which had not been considered as a key quantitative value, as it was rather taken as a mere indicator of the therapeutic (radiotherapeutic) effect, not a direct indicator of the prognosis for the cancer itself. Methods: Forty patients with rectal cancer in the lower rectal region underwent two series of FDG-PET study before and after pre-operative radiotherapy. Their SUVs were calculated from FDG-PET data and compared with the results of the long-term follow-up of the patients as well as with histopathological outcomes. Results: All 40 patients had high FDG uptake before radiotherapy. The mean value of SUV before radiotherapy (SUV 1) was 7.6. After radiotherapy, the mean value of SUV (SUV2) decreased to 4.2. There was a significant difference in SUV2 between the groups with and without recurrence (p < 0.05), however, SUV1 or SUV ratio (SUV2/SUV1) displayed no significant difference with the incidence of recurrence. Conclusion: SUV2 was considered to be a good prognostic indicator for long-term prognosis of rectal cancer patients. SUV I nor SUV ratio SUV2/SUV1 did not have the equivalent prognostic usefulness. Subsets of patients with SUV2 greater than 3.2 should be observed closely.
引用
收藏
页码:409 / 416
页数:8
相关论文
共 21 条
  • [1] Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings
    Abdel-Nabi, H
    Doerr, RJ
    Lamonica, DM
    Cronin, VR
    Galantowicz, P
    Carbone, GM
    Spaulding, MB
    [J]. RADIOLOGY, 1998, 206 (03) : 755 - 760
  • [2] Akhurst T, 1999, SEMIN ONCOL, V26, P577
  • [3] Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer
    Bender, H
    Bangard, N
    Metten, N
    Bangard, M
    Mezger, J
    Schomburg, A
    Biersack, HJ
    [J]. HYBRIDOMA, 1999, 18 (01): : 87 - 91
  • [4] EHRENKAUFER RE, 1984, J NUCL MED, V25, P333
  • [5] Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil
    Findlay, M
    Young, H
    Cunningham, D
    Iveson, A
    Cronin, B
    Hickish, T
    Pratt, B
    Husband, J
    Flower, M
    Ott, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 700 - 708
  • [6] Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases
    Fong, YM
    Saldinger, PF
    Akhurst, T
    Macapinlac, H
    Yeung, H
    Finn, RD
    Cohen, A
    Kemeny, N
    Blumgart, LH
    Larson, SM
    [J]. AMERICAN JOURNAL OF SURGERY, 1999, 178 (04) : 282 - 287
  • [7] Fukunaga T, 1998, J NUCL MED, V39, P1002
  • [8] Cancer statistics, 2001
    Greenlee, RT
    Hill-Harmon, MB
    Murray, T
    Thun, M
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2001, 51 (01) : 15 - 36
  • [9] HABERKORN U, 1993, J NUCL MED, V34, P12
  • [10] Monitoring response to therapy in cancer using [18F]-2-fluouo-2-deoxy-D-glucose and positron emission tomography:: an overview of different analytical methods
    Hoekstra, CJ
    Paglianiti, I
    Hoekstra, OS
    Smit, EF
    Postmus, PE
    Teule, GJJ
    Lammertsma, AA
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (06) : 731 - 743